Cargando…

Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research

Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients’ immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Schumacher, Thomas, Ruehland, Claus, Schultheiss, Christine, Brinkman, Marc, Roedel, Franz, Reiser, Christian O. A., Hess, Juergen, Reichel, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Master Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614679/
https://www.ncbi.nlm.nih.gov/pubmed/23675044
_version_ 1782264891375091712
author Schumacher, Thomas
Ruehland, Claus
Schultheiss, Christine
Brinkman, Marc
Roedel, Franz
Reiser, Christian O. A.
Hess, Juergen
Reichel, Christoph
author_facet Schumacher, Thomas
Ruehland, Claus
Schultheiss, Christine
Brinkman, Marc
Roedel, Franz
Reiser, Christian O. A.
Hess, Juergen
Reichel, Christoph
author_sort Schumacher, Thomas
collection PubMed
description Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients’ immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus on immunotherapeutic vaccination and discuss the advantages and disadvantages of different strategies to deliver tumor-specific T-cell epitopes. A particular focus will be put on virus-like particles (VLPs) as vehicle to deliver tumor-specific epitopes in the context of full-length proteins, as multi-epitope constructs or as individual tumor-associated T-cell epitopes. VLPs represent non-infectious and non-replicating antigen delivery systems devoid of any nucleic acid. They constitute innovative immunotherapeutic agents against cancer due to their superior, adjuvant-like antigenicity. We will present various tumor-associated antigens currently in different stages of development including survivin, as promising candidates for targeted tumor therapies.
format Online
Article
Text
id pubmed-3614679
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Master Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36146792013-05-01 Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research Schumacher, Thomas Ruehland, Claus Schultheiss, Christine Brinkman, Marc Roedel, Franz Reiser, Christian O. A. Hess, Juergen Reichel, Christoph Int J Biomed Sci Article Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients’ immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus on immunotherapeutic vaccination and discuss the advantages and disadvantages of different strategies to deliver tumor-specific T-cell epitopes. A particular focus will be put on virus-like particles (VLPs) as vehicle to deliver tumor-specific epitopes in the context of full-length proteins, as multi-epitope constructs or as individual tumor-associated T-cell epitopes. VLPs represent non-infectious and non-replicating antigen delivery systems devoid of any nucleic acid. They constitute innovative immunotherapeutic agents against cancer due to their superior, adjuvant-like antigenicity. We will present various tumor-associated antigens currently in different stages of development including survivin, as promising candidates for targeted tumor therapies. Master Publishing Group 2007-09 /pmc/articles/PMC3614679/ /pubmed/23675044 Text en © Thomas Schumacher et al. Licensee Master Publishing Group http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Schumacher, Thomas
Ruehland, Claus
Schultheiss, Christine
Brinkman, Marc
Roedel, Franz
Reiser, Christian O. A.
Hess, Juergen
Reichel, Christoph
Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
title Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
title_full Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
title_fullStr Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
title_full_unstemmed Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
title_short Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
title_sort advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine research
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614679/
https://www.ncbi.nlm.nih.gov/pubmed/23675044
work_keys_str_mv AT schumacherthomas advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT ruehlandclaus advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT schultheisschristine advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT brinkmanmarc advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT roedelfranz advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT reiserchristianoa advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT hessjuergen advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch
AT reichelchristoph advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch